Literature DB >> 18316345

Response assessment in solid tumours: a comparison of WHO, SWOG and RECIST guidelines.

P K Julka1, D C Doval, S Gupta, G K Rath.   

Abstract

The primary objective of this study was to evaluate the applicability of World Health Organization (WHO), Southwest Oncology Group (SWOG) and Response Evaluation Criteria in Solid Tumours (RECIST) guidelines when evaluating the response of cytotoxic agents in solid tumours. Patients with a solid tumour who were planned for standard chemotherapy, were aged more than 18 years and had an anticipated life expectancy of at least 12 weeks were included in the study. Patients received chemotherapy using standard protocols and were required to have a pre-treatment evaluation of tumour burden on CT. Subsequent response assessment was performed every two cycles. Each patient was evaluated by all three criteria (WHO, SWOG and RECIST) to check the applicability of a specific criterion during routine clinical practice. In total, 80 patients were included in the study. Out of these, the response criteria displayed discordance in 17 (21%) patients. Of these 17 patients, RECIST criteria were not applicable for 6 patients owing to the small lesion size. The present study shows that a particular guideline may be useful in establishing uniformity of evaluation in a desired study population but may not be the best for that population during routine clinical practice. It also indicates that each of the guidelines has its own applicability and that no guideline can outweigh the other during routine clinical practice.

Entities:  

Mesh:

Year:  2008        PMID: 18316345     DOI: 10.1259/bjr/32785946

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  10 in total

1.  Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review.

Authors:  Zohreh Maghsoomi; Zahra Emami; Ramin Malboosbaf; Mojtaba Malek; Mohammad E Khamseh
Journal:  BMC Cancer       Date:  2021-05-20       Impact factor: 4.430

Review 2.  Imaging of neuroendocrine gastroenteropancreatic tumours.

Authors:  R Graziani; A Brandalise; M Bellotti; R Manfredi; A Contro; M Falconi; L Boninsegna; R Pozzi Mucelli
Journal:  Radiol Med       Date:  2010-03-09       Impact factor: 3.469

3.  The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer.

Authors:  G Kasymjanova; N MacDonald; J S Agulnik; V Cohen; C Pepe; H Kreisman; R Sharma; D Small
Journal:  Curr Oncol       Date:  2010-08       Impact factor: 3.677

4.  Evaluation of cancer treatment in the abdomen: Trends and advances.

Authors:  Silanath Peungjesada; Hubert H Chuang; Srinivasa R Prasad; Haesun Choi; Evelyne M Loyer; Yulia Bronstein
Journal:  World J Radiol       Date:  2013-03-28

Review 5.  Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer.

Authors:  Edward B Garon
Journal:  Lung Cancer       Date:  2012-07-12       Impact factor: 5.705

6.  A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy.

Authors:  Sung Han Kim; Sohee Kim; Jungnam Joo; Ho Kyung Seo; Jae Young Joung; Kang Hyun Lee; Jinsoo Chung
Journal:  BMC Cancer       Date:  2016-08-02       Impact factor: 4.430

7.  Image-based diagnosis of residual or recurrent nasopharyngeal carcinoma may be a phantom tumor phenomenon.

Authors:  Ching-Chi Lee; Jih-Chin Lee; Wen-Yen Huang; Chun-Jung Juan; Yee-Min Jen; Li-Fan Lin
Journal:  Medicine (Baltimore)       Date:  2021-02-26       Impact factor: 1.817

8.  In Silico Model Estimates the Clinical Trial Outcome of Cancer Vaccines.

Authors:  Orsolya Lőrincz; József Tóth; Levente Molnár; István Miklós; Kata Pántya; Mónika Megyesi; Eszter Somogyi; Zsolt Csiszovszki; Enikő R Tőke
Journal:  Cells       Date:  2021-11-05       Impact factor: 6.600

9.  Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature.

Authors:  Melissa C Paoloni; Anita Tandle; Christina Mazcko; Engy Hanna; Stefan Kachala; Amy Leblanc; Shelley Newman; David Vail; Carolyn Henry; Douglas Thamm; Karin Sorenmo; Amin Hajitou; Renata Pasqualini; Wadih Arap; Chand Khanna; Steven K Libutti
Journal:  PLoS One       Date:  2009-03-30       Impact factor: 3.240

10.  Initial computed tomography imaging details during first-line systemic therapy is of significant prognostic value in patients with naïve, unresectable metastatic renal cell carcinoma.

Authors:  Sung Han Kim; Weon Seo Park; Sun Ho Kim; Ho Kyung Seo; Jae Young Joung; Kang Hyun Lee; Jinsoo Chung
Journal:  PLoS One       Date:  2017-05-31       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.